Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
No open-market purchases or sales by Faeth Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Faeth Therapeutics, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Of which not filed for Q4 2024 | Q4 2024 | Change |
|---|---|---|---|---|
| Holders | 19 | 1 | 24 | +6 |
| Shares | 2.21M | 20.0K | 2.36M | +177.3K (+8.1%) |
| Value | $1.32M | $12.0K | $1.16M | −$149.8K (−11.5%) |
1 institution that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (7)
Institutions that held Faeth Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Catalio Capital Management, LP | 294,374 | $144.3K | 0.03% |
| NWF Advisory Services Inc. | 16,514 | $8.09K | 0.00% |
| Raymond James Financial Inc | 14,000 | $6.86K | 0.00% |
| HRT Financial LP | 11,600 | $5.00K | 0.00% |
| BNP Paribas Arbitrage, SA | 160 | $78 | 0.00% |
| SBI Securities Co., Ltd. | 71 | $35 | 0.00% |
| UBS Group AG | 2 | $1 | 0.00% |
Sold out (1)
Institutions that held Faeth Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| National Bank of Canada | 45,575 | $27.3K |
Not filed for Q4 2024 yet (1)
Institutions that held Faeth Therapeutics, Inc. at the end of Q3 2024 and haven't filed a 13F for Q4 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Raymond James & Associates | 20,000 | $12.0K |